Theravance Biopharma (TBPH) EBIAT: 2013-2025
Historic EBIAT for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.6 million.
- Theravance Biopharma's EBIAT rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 159.40%. This contributed to the annual value of -$56.4 million for FY2024, which is 2.22% down from last year.
- Theravance Biopharma's EBIAT amounted to $3.6 million in Q3 2025, which was down 93.41% from $54.8 million recorded in Q2 2025.
- Theravance Biopharma's EBIAT's 5-year high stood at $916.6 million during Q3 2022, with a 5-year trough of -$86.5 million in Q1 2021.
- Moreover, its 3-year median value for EBIAT was -$12.7 million (2024), whereas its average is -$6.1 million.
- In the last 5 years, Theravance Biopharma's EBIAT soared by 1,739.48% in 2022 and then slumped by 100.98% in 2023.
- Over the past 5 years, Theravance Biopharma's EBIAT (Quarterly) stood at -$57.8 million in 2021, then skyrocketed by 75.34% to -$14.3 million in 2022, then soared by 40.31% to -$8.5 million in 2023, then tumbled by 82.46% to -$15.5 million in 2024, then surged by 128.47% to $3.6 million in 2025.
- Its EBIAT stands at $3.6 million for Q3 2025, versus $54.8 million for Q2 2025 and -$13.6 million for Q1 2025.